Utter Christine Marie 4

What Happened
Christine Marie Utter, Senior Vice President and Chief Accounting Officer of PTC Therapeutics (PTCT), exercised 19,686 stock options and sold the 19,686 shares on 2026-06-17. The exercise reflected a cash outlay of $505,733 (strike $25.69/share) and the subsequent open-market sale generated gross proceeds of $1,487,474 (sale price $75.56/share). The filing shows the derivative conversion associated with the exercise (reported as disposed at $0), indicating the options were converted into shares and those shares were sold the same day.

Key Details

• Transaction date: 2026-06-17 (filed on 2026-06-22) — filing appears late vs. the typical 2-business-day Form 4 deadline.
• Exercise: 19,686 option shares exercised at $25.69 each; total cost $505,733.
• Sale: 19,686 shares sold in open market at $75.56 each; gross proceeds $1,487,474.
• Shares owned after transaction: Not disclosed in this Form 4 filing.
• Footnotes: Transaction was effected under a written Rule 10b5-1 trading plan adopted March 17, 2026 (F1). The option was originally granted Feb 15, 2024 and vests over four years with scheduled quarterly vesting (F2).
• Derivative detail: The filing lists a derivative conversion line (disposed at $0) consistent with exercising options into shares and selling them the same day.

Context
This was an option exercise followed by an immediate sale (often called a cashless exercise or same-day disposition). Such transactions are routine for executives exercising vested option awards to realize gains; the use of a 10b5-1 plan indicates the sale was executed under a pre-established trading arrangement. The late filing may matter to compliance observers but does not, by itself, indicate anything about company fundamentals.